In a nutshell This study investigated the link between vitamin D deficiency and thyroid diseases in patients with type 2 diabetes (T2D). It was found that vitamin D deficiency is associated with a higher risk of thyroid diseases in these patients. Some background Diabetes and thyroid diseases are the two most common hormonal disorders. The thyroid...
Read More
In a nutshell This study investigated factors that might increase the risk of developing diabetic retinopathy (DR) in patients with type 1 diabetes (T1D). It was determined that older age at diagnosis, high HbA1c levels (measures average blood glucose over the last 3 months) 1 year after diagnosis, in addition to severe hypoglycemia (dangerously low...
Read MoreIn a nutshell This phase 3 clinical trial is examining the safety and effectiveness of efpeglenatide for people with type 2 diabetes (T2D) that is not controlled with diet and exercise. The main outcome to be measured is change in HbA1c (measures average blood glucose over the last 3 months). The details People with T2D can control their...
Read MoreIn a nutshell This phase 3 clinical trial is investigating the effects of sotagliflozin on cardiovascular disease and kidney disease, in people with type 2 diabetes (T2D). The main outcome to be tested is the time until a major adverse cardiovascular event (MACE) or heart failure occurs. The details Two proteins, called SGLT1 and SGLT2, are important...
Read More
In a nutshell This study examined the link between HbA1c levels (average blood glucose over the last 3 months) measured in the first trimester of pregnancy and gestational diabetes mellitus (GDM; diabetes first occurring in pregnancy). It was determined that increased HbA1c levels in the first trimester were associated with an increased risk of...
Read MoreIn a nutshell This trial is examining the effects of different diabetes self-management strategies in African American and Hispanic women with type 2 diabetes (T2D). The main outcomes to be measured will be the change in physical activity levels and the change in HbA1c (measures average blood glucose over the last 3 months). This study is being conducted...
Read MoreIn a nutshell This trial is examining the effect of group visits for diabetes in Hispanic adults with diabetes. The main outcomes to be measured will be change in HbA1c (measures average blood glucose over the last 3 months), BMI (measure of weight that takes height into account) and blood pressure. This trial will take place in Houston, TX. The details...
Read MoreIn a nutshell This phase 3 clinical trial is investigating the effects of pemafibrate (Parmodia) on cardiovascular disease in people with type 2 diabetes (T2D). The main outcome to be measured will be the number of patients that experience a heart attack, stroke, death from cardiovascular causes, or who have to be hospitalized for unstable angina (severe...
Read MoreIn a nutshell This phase 3 clinical trial is investigating the effects of relamorelin on diabetic gastroparesis. The main outcomes to be measured will be the percentage of patients that experience a reduction in the severity of symptoms, and the percentage that experience a reduction in vomiting. The details In gastroparesis the stomach takes too long...
Read MoreIn a nutshell This clinical trial is investigating the effects of an artificial pancreas (AP) system on brain function in older adults with type 1 diabetes (T1D). The main outcome to be measured will be change in alternate fuel uptake by the brain during hypoglycemia (dangerously low blood glucose). The details Glucose is used as fuel by the brain and...
Read MoreIn a nutshell This phase 1 and 2 clinical trial is investigating the impact of using stem cells and drugs that suppress the immune system in type 1 diabetes (T1D). The main outcomes to be measured will be the change in production of insulin by the pancreas, and any serious side effects of treatment. This study is being conducted in Canada. The details...
Read MoreIn a nutshell This phase 3 clinical trial is investigating the safety and effectiveness of dapagliflozin (Forxiga) and saxagliptin (Onglyza) in young people with type 2 diabetes (T2D). The main outcome to be measured will be change in HbA1c (measures average blood glucose over the last 3 months) after 6 months of treatment. The details Dapagliflozin...
Read More
